Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

Condition:   Head and Neck Cancer
Interventions:   Procedure: Surgical resection of primary tumor;   Radiation: Adjuvant radio(-chemo)therapy;   Drug: Neoadjuvant Nivolumab;   Drug: Adjuvant Nivolumab;   Drug: Adjuvant Nivolumab and Ipilimumab
Sponsors:   Universitätsklinikum Hamburg-Eppendorf;   University Hospital, Essen;   Westpfalz-Clinical Center GmbH;   Charite University, Berlin, Germany
Recruiting

https://ift.tt/2OcPfwi